Rankings
▼
Calendar
CLDX
Celldex Therapeutics, Inc.
$2B
Q1 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
Gross Profit
-$50M
-3837.5% margin
Operating Income
-$36M
-2740.1% margin
Net Income
-$35M
-2661.0% margin
EPS (Diluted)
$-5.27
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$35M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$302M
Total Liabilities
$42M
Stockholders' Equity
$260M
Cash & Equivalents
$63M
Revenue Segments
Pd1 Immune Checkpoint Inhibitor
$400,000
100%
← FY 2016
All Quarters
Q2 2016 →
CLDX Q1 2016 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena